Your session is about to expire
← Back to Search
INL-001 (bupivacaine hydrochloride) implant for Postoperative Pain
Phase 3
Waitlist Available
Research Sponsored by Innocoll
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
Awards & highlights
Study Summary
This trial looks at the safety and how well the body tolerates a new pain medication given as an implant following various types of surgery.
Eligible Conditions
- Postoperative Pain
- Ventral Hernia
- Tummy Tuck
- Hysterectomy
- Colectomy
- Breast Reduction Surgery
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Evaluate the safety and tolerability
Secondary outcome measures
AUC
AUC0-∞
Cmax
+4 moreOther outcome measures
15-item Quality of Recovery (QoR-15) Questionnaire
Opioid-related Symptom Distress Scale (OR-SDS)
Patient Global Assessment (PGA) as Related to Postoperative Pain
+5 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: INL-001 (bupivacaine hydrochloride) implantExperimental Treatment1 Intervention
INL-001 (bupivacaine hydrochloride) implant
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INL-001 (bupivacaine hydrochloride) implant
2021
Completed Phase 3
~100
Find a Location
Who is running the clinical trial?
InnocollLead Sponsor
20 Previous Clinical Trials
4,890 Total Patients Enrolled
5 Trials studying Postoperative Pain
326 Patients Enrolled for Postoperative Pain
Anne ArriagaStudy DirectorLotus Clinical Research
1 Previous Clinical Trials
366 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger